Archives: Summit Talks

Interview Notes

• Andrew D. Hershey, MD
• Cincinnati Headache Center
• ClinicalTrials.gov
• American Headache Society
• International Headache Society
• National Pain Advocacy Center
• Study: “Comparison of continuous headache features in youth with migraine, new daily persistent headache, and persistent post-traumatic headache”
• Article: “Chronic Pain: What You Need To Know”

Treatments Mentioned

• Anti-seizure medicines
• CGRP monoclonal antibodies (mAbs)
• Cognitive behavioral therapy (CBT)
• Exercise
• Healthy eating
• Hydration
• Neuromodulation
• Pain modulation devices
• Regular sleep
• TENS devices
• Tricyclic antidepressants
• Vagus (vagal) nerve stimulation

Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.

This is a Spanish translation of an expert interview from the Migraine World Summit 2024. All interviews have been carefully translated and medically reviewed.

Nota editorial: Hay veces que la traducción dice “cefalea diaria persistente nueva” pero la clasificación correcta, de acuerdo a la clasificación internacional de trastornos de cefalea en español  es “cefalea diaria persistente de novo”.

Interview Notes

• Kristen K. Steenerson, MD
• Steenerson Clinic
• Stanford Medicine
• Book: Victory Over Vestibular Migraine: The ACTION Plan for Healing & Getting Your Life Back
• Book: Rock Steady: Healing Vertigo or Tinnitus with Neuroplasticity 
• Study: “Galcanezumab for vestibular migraine”

Treatments Mentioned

• Aerobic exercise
• Antidepressants
• Anti-nausea medications
• Anti-seizure medications
• Blood pressure medications
• CGRP inhibitors
• Cognitive behavioral therapy (CBT)
• Cool compress
• Coenzyme Q10 (CoQ10)
• Dopamine antagonist
• Essential Oils
• Feverfew
• Grounding techniques
• Magnesium
• Mindfulness
• Meditation
• Remote electrical neuromodulation
• Strength training
• Trigeminal nerve stimulation
• Triptans
• Vagus (vagal) nerve stimulation
• Vestibular physical therapists
• Vitamin B2 (riboflavin)

Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.

This is a Spanish translation of an expert interview from the Migraine World Summit 2024. All interviews have been carefully translated and medically reviewed.

Interview Notes

• Walter J. Koroshetz, MD
• National Institute of Neurological Disorders and Stroke (NINDS)
• The BRAIN Initiative
• NIH HEAL Initiative
• C. Miller Fisher
• Article: “Entering a New Realm of Migraine Treatment, Research Priorities”
• Article: “Scientists Find New Pain-Suppression Center in the Brain”
• Interview: “Michael Oshinsky, AHS 2021: Migraine Research Update – NIH Roadmap”
• Podcast: “Understanding and Managing Migraine in Kids and Teens”
• X (Twitter): @NINDSdirector

Treatments Mentioned

• CGRP Inhibitors
• Nonaddictive pain medications
• Opioids
• Vagus (vagal) nerve stimulation

Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.

This is a Spanish translation of an expert interview from the Migraine World Summit 2024. All interviews have been carefully translated and medically reviewed.

Interview Notes

• Robert P. Cowan, MD, FAAN, FAHS
• EudraVigilance (European Medicines Agency)
• FDA MedWatch (or 800-438-1985)
• Food and Drug Administration (FDA)
• NHS (side effect reporting)

Treatments Mentioned

• Atogepant (Qulipta)
• CGRP inhibitors
• CGRP monoclonal antibodies (mAbs)
• CGRP small-molecule receptor antagonists (gepants)
• Eptinezumab (Vypeti)
• Erenumab (Aimovig)
• Fremanezumab (Ajovy)
• Galcanezumab (Emgality)
• Laxatives
• Topiramate (Topamax)
• Triptans

Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.

This is a Spanish translation of an expert interview from the Migraine World Summit 2024. All interviews have been carefully translated and medically reviewed.

Interview Notes

• Robert Bonakdar, MD
• American Nutrition Association
• Complementary & Integrative Medicine Special Interest Section
• U.S. Pharmacopeia (USP)
• NSF (The Public Health and Safety Organization)
• Longvida supplement
• Migraine Nutrition and Supplementation Guide
• Scripps Article: “Integrative Approaches to Headache Management”
• Book: The H.E.R.B.A.L. Guide: Dietary Supplement Resources for the Clinician
• Case Report: “Case Report: Initial Successful Treatment of Migraine and Irritable Bowel Syndrome With a Low-FODMAP Diet”
• Study: “The association between dietary fiber intake and severe headaches or migraine in US adults”
• Study: “Effect of vitamin D therapy in addition to amitriptyline on migraine attacks in pediatric patients”
• Study: “Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine”
• Study: “A double-blind, randomized, and placebo-controlled clinical trial with omega-3 polyunsaturated fatty acids (OPFA ɷ-3) for the prevention of migraine in chronic migraine patients using amitriptyline”
• Study on butterbur: “Petasites for migraine prevention: New data on mode of action, pharmacology and safety. A narrative review”
• Study on dietary omega-3: “Dietary alteration of n-3 and n-6 fatty acids for headache reduction in adults with migraine: randomized controlled trial”
• Study: “Comparison between the efficacy of ginger and sumatriptan in the ablative treatment of the common migraine”

Treatments Mentioned

• Amitriptyline
• Antioxidants
• Boswellia
• Butterbur (Petadolex)
• Coenzyme Q10 (CoQ10)
• Curcumin (Longvida)
• Diamine oxidase
• Feverfew
• Fiber
• Ginger
• Ginkgo
• Gluten-free diet
• HeadacheFree Complete Multivitamin
• Iron
• Ketorolac (Toradol)
• Magnesium
• Melatonin
• Migra-Well
• Omega-3 fatty acids (fish oil)
• Probiotics
• Riboflavin (vitamin B2)
• Thiamin
• Triptans
• Vitamin D
• Zinc

Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.

This is a Spanish translation of an expert interview from the Migraine World Summit 2024. All interviews have been carefully translated and medically reviewed.

Interview Notes

• The Migraine Trust
• Coalition of Headache and Migraine Patients (CHAMP)
• Study: “Dismissed for too long: The impact of migraine on children & young people”
• The Migraine Trust article: “Research Reveals That Over a Third of People Have Experienced Discrimination at Work Because of Their Migraines”
• Report: “The State of the Migraine Nation: What Is the Impact of Migraine in the U.K.? Rapid Research Review”
• The Migraine Trust toolkits
• The Migraine Trust: Get involved
• Harvard Business Review article: “Migraines Are a Serious Problem. Employers Can Help”

Treatments Mentioned

• Atogepant (Qulipta, Aquipta in the U.K.)
• CGRP monoclonal antibodies (mAbs)
• CGRP small-molecule receptor antagonists (gepants)
• Rimegepant (Nurtec, Vydura in the U.K.)
• Ubrogepant (Ubrelvy)

Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.

Interview Notes

• Richard B. Lipton, MD
• American Headache Society
• Montefiore Headache Center
• Headache in Clinical Practice 
• Study:  “The association between migraine and dementia – a national register-based matched cohort study”
• Study: “Headache disorder and the risk of dementia: a systematic review and meta-analysis of cohort studies”
• Study: “Cortical spreading depression closes paravascular space and impairs glymphatic flow: Implications for migraine headache”
• Study: “Migraine pharmacological treatment and cognitive impairment: Risks and benefits”
• Study: “Headache – A window to dementia: An unexpected twist”
• Article: “Migraine Sleep Quality Examined in New Study”

Treatments Mentioned

• Amitriptyline
• Exercise
• Mediterranean diet
• Nortriptyline
• Omega-3 fatty acids
• Sleep
• Topiramate (Topamax)

Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.

This is a Spanish translation of an expert interview from the Migraine World Summit 2024. All interviews have been carefully translated and medically reviewed.

Interview Notes

• Rashmi B. Halker Singh, MD
• Mayo Clinic – Arizona
• American Academy of Neurology
• American Headache Society
• Resident Education for Assessment and Care for Headache (REACH) Program
• Women’s Leadership Development 
• Scottsdale Headache Symposium
• Journal: Headache
• American Migraine Foundation
• International Headache Society

Treatments Mentioned

• Amitriptyline
• Cervical spine injections
• Chiropractic
• Cognitive behavioral therapy (CBT)
• Duloxetine
• Gabapentin
• Massage therapy
• Nerve blocks
• Neurosurgical intervention
• OnabotulinumtoxinA (Botox)
• PM&R (physical medicine and rehabilitation) physician
• Physical therapy (PT)
• Relaxation therapy
• SEEDS ( Sleep, Exercise, Eating, Drinking, & Stress Management)
• TMJ specialist: Temporomandibular disorders
• Venlafaxine (Effexor)

Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.

This is a Spanish translation of an expert interview from the Migraine World Summit 2024. All interviews have been carefully translated and medically reviewed.

Interview Notes

• Study: “Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA”
• Article: “PACAP-Targeted Antibody Lu AG09222 Demonstrates Positive Results in Phase 2 Migraine Trial”
• Study: “PAR2 activation in the dura causes acute behavioral responses and priming to glyceryl trinitrate in a mouse migraine model”

Treatments Mentioned

• Almotriptan (Axert)
• Amitriptyline
• Atogepant (Qulipta)
• CGRP inhibitors
• CGRP monoclonal antibodies (mAbs)
• CGRP small-molecule receptor antagonists (gepants)
• Eletriptan (Relpax)
• Eptinezumab (Vyepti)
• Erenumab (Aimovig)
• Fremanezumab (Ajovy)
• Frovatriptan (Frova)
• Galcanezumab (Emgality)
• Naratriptan (Amerge)
• Propranolol
• Rimegepant (Nurtec)
• Rizatriptan (Maxalt)
• Sumatriptan (Imitrex)
• Topiramate (Topamax)
• Triptans
• Ubrogepant (Ubrelvy)
• Zavegepant (Zavzpret)
• Zolmitriptan (Zomig)

Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.

This is a Spanish translation of an expert interview from the Migraine World Summit 2024. All interviews have been carefully translated and medically reviewed.

Interview Notes

• Migraine at Work
• Book: Headache: What Do I Do Now? 
• Harvard Business Review article: “Migraines Are a Serious Problem. Employers Can Help”
• Fujitsu Headache Project article: “Migraine in the Workplace”
• Article: “Fujitsu Honored by the International Headache Society – Global Patient Advocacy Coalition as a World Leader in Migraine Workplace Awareness, Education, and Employee Support Programs”
• Global Patient Advocacy Coalition (GPAC)
• American Migraine Foundation
• X (Twitter): @obegassededhaem

Treatments Mentioned

• Workplace accommodations

Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.

This is a Spanish translation of an expert interview from the Migraine World Summit 2024. All interviews have been carefully translated and medically reviewed.

Interview Notes

• New York State Neurological Society
• American Headache Society
• Weill Cornell School of Medicine
• NewYork Presbyterian Hospital
• X (Twitter): @mrobbinsmd
• Press Release: “First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention”
• Study: “Comparing the efficacy and safety of galcanezumab versus rimegepant for prevention of episodic migraine: Results from a randomized, controlled clinical trial”
• MWS Interview: “Planning for Pregnancy With Migraine”

Treatments Mentioned

• Antibiotics
• Antifungal medications
• Celecoxib (Elyxyb)
• Atogepant (Qulipta)
• CGRP Inhibitors
• CGRP monoclonal antibodies (mAbs)
• CGRP small-molecule receptor antagonists (gepants)
• Diclofenac (Cambia)
• Dihydroergotamine (DHE and Trudhesa)
• Galcanezumab (Emgality)
• Lasmiditan (Reyvow)
• Neuromodulation devices
• Nirmatrelvir/ritonavir (Paxlovid)
• Rimegepant (Nurtec)
• Triptans
• Ubrogepant (Ubrelvy)
• Zavegepant (Zavzpret)

Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.

This is a Spanish translation of an expert interview from the Migraine World Summit 2024. All interviews have been carefully translated and medically reviewed.

Interview Notes

• Miles For Migraine
• Alliance for Headache Disorders Advocacy
• Headache on the Hill
• “Spoons”

 

Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.

This is a Spanish translation of an expert interview from the Migraine World Summit 2024. All interviews have been carefully translated and medically reviewed.